Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.45 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.45 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | DHODH | Q02127 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.41 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL559668 | 0.91 | MAPT (0.52) | MAPTMEN1KMT2ACASP3SENP7 | |
| SCHEMBL238194 | 0.86 | LTC4S (0.47) | MAPTMEN1KMT2ACASP3SENP7 | |
| SCHEMBL2892434 | 0.84 | CES1 (0.50) | MAPTMEN1KMT2AHPGDHDAC8 | |
| SCHEMBL1724154 | 0.84 | LTC4S (0.49) | MAPTMEN1KMT2AHPGDABL1 | |
| SCHEMBL559536 | 0.80 | MAPT (0.50) | MAPTMEN1KMT2ACASP3SENP7 | |
| SCHEMBL2884838 | 0.80 | ALDH1A1 (0.47) | MAPTMEN1KMT2ACASP3SENP7 | |
| SCHEMBL1721644 | 0.80 | MDM2 (0.42) | MAPTMEN1KMT2ACASP3SENP7 | |
| SCHEMBL1723626 | 0.80 | P2RX7 (0.43) | MAPTMEN1KMT2ACASP3SENP7 | |
| SCHEMBL2884732 | 0.79 | KMT2A (0.55) | MAPTMEN1KMT2AHPGDNPC1 | |
| SCHEMBL230366 | 0.79 | MAPT (0.51) | MAPTMEN1KMT2ACASP3SENP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2429994-A1 | BIS AROMATIC COMPOUNDS FOR USE AS LTC4 SYNTHASE INHIBITORS | Biolipox AB (SE) | 2012-03-21 | — | — | EP | disclosed |
| US-20120035217-A1 | Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors | BIOLIPOX AB (SW) | 2012-02-09 | — | — | US | disclosed |
| EP-2406223-A2 | BIS AROMATIC COMPOUNDS FOR USE AS LTC4 SYNTHASE INHIBITORS | Biolipox AB (SE) | 2012-01-18 | — | — | EP | disclosed |
| US-20110319431-A1 | Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors | BIOLIPOX AB (SW) | 2011-12-29 | — | — | US | disclosed |
| WO-2010103297-A2 | BIS AROMATIC COMPOUNDS FOR USE AS LTC4 SYNTHASE INHIBITORS | BIOLIPOX AB (SE) | 2010-09-16 | — | — | WO | disclosed |
| WO-2010103283-A1 | BIS AROMATIC COMPOUNDS FOR USE AS LTC4 SYNTHASE INHIBITORS | BIOLIPOX AB (SE) | 2010-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035217-A1 | Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors | LTC4S, LTB4R2, LTB4R | MAPT 3787/4885MEN1 3988/4885KMT2A 3636/4885 |
| US-20110319431-A1 | Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors | LTC4S, LTB4R2, LTB4R | MAPT 3714/4885MEN1 4027/4885KMT2A 3835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.